Table 1.

Demographics, blood pressure profiles, treatments and outcomes of patients

	Controlled Hypertension (n = 115)	Uncontrolled Hypertension (n = 236)	P value	Non-Severe Covid-19 (n = 137)	Severe covid-19 (n = 214)	P value
Demographics
Age, year	52 ± 17	55 ± 26	0.473	50 ± 27	56 ± 30	0.053
Sex, men	41.2%	58.8%	0.033	51.2%	49.9%	0.231
BP on admission
SBP, mmHg	126 ± 18	144 ± 31	0.007	128 ± 10	130 ± 22	0.144
DBP, mmHg	81 ± 11	92 ± 18	0.043	80 ± 9	80 ± 15	0.556
MAP, mmHg	96 ± 13	97 ± 16	0.632	99 ± 20	97 ± 23	0.473
Comobidities
Diabetes mellitus	32.9%	25.6%	0.063	14.6%	34.5%	0.003
CAD	32.9%	17.6%	0.556	32.9%	27.6%	0.556
CKD	14.1%	33.3%	0.188	14.1%	33.3%	0.188
Heart failure	10.6%	17.6%	0.631	10.6%	17.6%	0.631
Antihypertensive drugs on admission
AdCEis/ARBs	60.5%	64.2%	0.152	60%	62.3%	0.209
Beta blockers	18.5%	25%	0.131	25.2%	22.3%	0.440
CCBs	42%	43.1%	0.665	44.5%	46.8%	0.556
Diuretics	22.3%	19.3%	0.154	23.1%	18,3%	0.188
Any of drugs above	12.3%	27.9%	0.045	33.4%	27%	0.052
Other medications
Glucocorticoid	86.9%	83.8%	0.822	87.5%	92.5%	0.082
Anticoagulant	52.1%	55.1%	0.898	36.49%	84.1%	0.000
BP Profile during hospitalization
MAPCV	2.1 ± 2.85	3.27 ± 4.9	0.002	2.9 ± 3.77	1.88 ± 2.42	0.000
High BPV	40.2%	59.8%	0.003	68.4%	31.6%	0.005
Outcome
In-hospital mortality	16.52%	46.08%	0.003	8.02%	37.8%	0.000

ABP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, CAD coronary artery disease, CKD chronic kidney disease, ACEis angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers, CCBs calcium channel blockers, MAPCV mean arterial pressure coefficient of variation, BPV blood pressure variability